Mechanisms of Negative Inotropic Effects of Class Ic Antiarrhythmic Agents: Comparative Study of the Effects of Flecainide and Pilsicainide on Intracellular Calcium Handling in Dog Ventricular Myocardium

Journal of Cardiovascular Pharmacology

Volumn 27, Issue 1, 1996, Pages 42-51

  Kihara, Yasuki ^a,b   Inoko, Moriaki ^a   Hatakeyama, Noboru ^a   Momose, Yasunori ^a   Sasayama, Shigetake ^a  

^a UNIVERSITY OF TOYAMA   (Japan)

^b KYOTO UNIVERSITY FACULTY OF MEDICINE   (Japan)

Author keywords

Aequorin; Calcium channels; Dog; Flecainide; Inotropic events antiarrhythmic agents; Intracellular calcium; Pilsicainide; Ventricular myocyte

Indexed keywords

ANTIARRHYTHMIC AGENT; CALCIUM CHANNEL; FLECAINIDE; PILSICAINIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CONTROLLED STUDY; DOG; DRUG EFFECT; DRUG MECHANISM; HEART ARRHYTHMIA; HEART MUSCLE CELL; HEART VENTRICLE; INOTROPISM; MUSCLE ISOMETRIC CONTRACTION; NONHUMAN; PRIORITY JOURNAL; SARCOPLASMIC RETICULUM;

ANIMALS; ANTI-ARRHYTHMIA AGENTS; CALCIUM; CALCIUM CHANNELS; DEPRESSION, CHEMICAL; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; FLECAINIDE; HEART VENTRICLES; LIDOCAINE; MYOCARDIAL CONTRACTION; MYOCARDIUM; SARCOLEMMA;

EID: 0030048292     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199601000-00008     Document Type: Article

References (61)

1. The Cardiac Arrhythmia Pilot Study (CAPS) Investigators. The cardiac arrhythmia pilot study. Am J Cardiol 1986:54: 91-5.
2. The Cardiac Arrhythmia Pilot Study (CAPS) Investigators. Effect of encainide, flecainide, imipramine and moricizine on ventricular arrhythmias during the year after acute myocardial infarction: the CAPS. Am J Cardiol 1988:61:501-9.
3. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med 1989;321:406-12.
4. The Cardiac Arrhythmia Suppression Trial (CAST) investigators. Mortality and morbidity inpatients receiving encainide, flecainide, or placebo. N Engl J Med 1991;324:781-8.
5. Herre JM, Titus C, Oeff M, et al. Inefficacy and proarrhythmic effects of flecainide and encainide for sustained ventricular tachycardia and ventricular fibrillation. Ann Intern Med 1990;113:671-6.
6. Gottlieb SS. The use of antiarrhythmic agents in heart failure: implications of CAST. Am Heart J 1989;118:1074-7.
7. dePaola AVA, Horowitz LN, Morganroth J, et al. Influence of left ventricular dysfunction on flecainide therapy. J Am Coll Cardiol 1987;9:163-8.
8. Katz AM. The cardiomyopathy of overload: a major determinant of prognosis in congestive heart failure. N Engl J Med 1990;322:100-10.
9. Josephson MA, Ikeda N, Singh BN. Effects of flecainide on ventricular function: clinical and experimental correlations. Am J Cardiol 1984;53:95B-100B.
10. Morganroth J, Anderson JL, Gentzkow GD. Classification by type of ventricular arrhythmia predicts frequency of adverse cardiac events from flecainide. J Am Coll Cardiol 1986;8:607-15.
11. Sami MH, Derbekyan VA, Lisbona R. Hemodynamic effects of encainide in patients with ventricular arrhythmia and poor ventricular function. Am J Cardiol 1983;52:507-11.
12. Singh BN, Courtney KR. The classification of antiarrhythmic mechanisms of drug action: experimental and clinical considerations. In: Zipes DP, Jalife J, eds. Cardiac electro physiology from cell to bedside. Philadelphia: W.B. Saunders, 1990:882-97.
13. Sheu SS, Blaustein MP. Sodium/calcium exchange and regulation of cell calcium and contractility in cardiac muscle, with a note about vascular smooth muscle. In: Fozzard HA, Haber E, Jennings RB, Katz AM, eds. The heart and cardiovascular system. New York: Raven Press, 1986:509-35.
14. Estes III NAM, Garan H, Ruskin JN, Electrophysiologic properties of flecainide acetate. Am J Cardiol 1984;53: 26B-9B.
15. Kvam DC, Banitt EH, Schmid JR. Antiarrhythmic and electrophysiologic actions of flecainide in animal models. Am J Cardiol 1984;53:22B-5B.
16. Campbell TJ, Vaughan Williams EM. Voltage- and time-dependent depression of maximum rate of depolarization of guinea-pig ventricular action potentials by two new antiarrhythmic drugs, flecainide and lorcainide. Cardiovasc Res 1983;17:251-8.
17. Roden DM, Woosley RL. Drug therapy. Flecainide. N Engl J Med 1986;315:36-41.
18. Yatani A, Akaike K. Effects of a new antiarrhythmic compound SUN 1165 (N-2,6-dimethylphenyl)-8-pyrrolizidinyl-acetamide hydrochloride) on the sodium currents in isolated single rat ventricular cells. Naunyn Schmiedebergs Arch Pharmacol 1984;326:163-8.
19. Hattori Y, Inomata N, Aisaka K, Ishihara T. Electrophysiological actions of N-(2,6-dimethylphenyl)-8-pyrrolizidine-acetamide hydrochloride hemihydrate (SUN 1165), a new antiarrhythmic agent. J Cardiovasc Pharmacol 1986;8:998-1002.
20. Inomata N, Ishihara T, Akaike N. SUN 1165: a new antiarrhythmic Na current blocker in ventricular myocytes of guinea-pig. Comp Biochem Physiol 1987;87C:237-43.
21. Hattori Y, Hidaka T, Aisaka K, Satoh F, Ishihara T. Effect of SUN 1165, a new potent antiarrhythmic agent, on the kinetics of rate-dependent block of Na channels and ventricular conduction of extrasystoles. J. Cardiovasc Pharmacol 1988;11:407-12.
22. Inomata N, Ishihara T, Akaike N. Different time courses of the blockade of sodium current by lignocaine and SUN 1165 in single myocytes isolated from guinea-pig atrium. Br J Pharmacol 1989;98:149-54.
23. Yokota M, Miyahara T, Enomoto N, et al. Pharmacokinetics and pharmacodynamics of an antiarrhythmic agent, SUN1165. Ther Res 1989;10:2135-47 (in Japanese).
24. Toyama J, Yamada K, Futamura Y, et al. Clinical effects of a new antiarrhythmic agent, SUN1165 in patients with ventricular arrhythmias. Ther Res 1989;10:2549-58 (in Japanese).
25. Kihara Y, Gwathmey JK, Grossman W, Morgan JP. Mechanisms of positive inotropic effects and delayed relaxation produced by DPI 201-106 in mammalian working myocardium: effects on intracellular calcium handling. Br J Pharmacol 1989;96:927-39.
26. Kihara Y, Morgan JP. A comparative study of three methods for intracellular loading of the calcium indicator aequorin in ferret papillary muscles. Biochem Biophys Res Commun 1989;162:402-7.
27. Kihara Y, Grossman W, Morgan JP. Direct measurement of changes in intracellular calcium transients during hypoxia, ischemia, and reperfusion of the intact mammalian heart. Circ Res 1989;65:1029-44.
28. Kihara Y, Inoko M, Sasayama S. L-Methionine augments myocardial contraction by sensitizing myofilament for calcium. Circ Res 1995;77:00-00.
29. Kihara Y, Sasayama S, Inoko M, Morgan JP. Sodium/ calcium exchange modulates intracellular calcium overload during posthypoxic reoxygenation in mammalian working myocardium: evidence from aequorin-loaded ferret ventricular muscles. J Clin Invest 1994;93:1275-84.
30. Kihara Y, Morgan JP. Intracellular calcium and ventricular fibrillation. Studies in the aequorin-loaded isovolumic ferret heart. Circ Res 1991;68:1378-89.
31. Inomata N, Ishihara T. Mechanism of inhibition by SUN 1165, a new Na channel blocking antiarrhythmic agent, of cardiac glycoside-induced triggered activity. Eur J Pharmacol 1988;145:313-22.
32. Esumi K, Nishida M, Shaw D, Smith TW, Marsh JD. NADH measurements in adult rat myocytes during simulated ischemia. Am J Physiol 1991;260:H1743-52.
33. Keung EC. Calcium current is increased in isolated adult myocytes from hypertrophied rat myocardium. Circ Res 1989;64:753-63.
34. Kleiman RB, House SR. Calcium currents in normal and hypertrophied isolated feline ventricular myocytes. Am J Physiol 1988;255:H1434-42.
35. Momose Y, Sasayama S. Effect of OPC-8490 on the membrane potentials and membrane currents of single guinea-pig myocytes. Cardiovasc Drugs Ther 1990;4:713-7.
36. Hatakeyama N, Momose Y, Ito Y. Effects of sevoflurane on contractile responses and electrophysiologic properties in canine single cardiac myocytes. Anesthesiology 1995;82: 559-65.
37. Blinks JR, Mattingly PH, Jewell BR, vanLeeuwen M, Harrer GC, Allen DG. Practical aspects of the use of aequorin as a calcium indicator: assay, preparation, microinjection and interpretation of signals. Methods Enzymol 1978;57:292-328.
38. 2+] transient, membrane potential and contraction. J Gen Physiol 1984;83:395-415.
39. Morgan JP. The effects of digitalis on intracellular calcium transients in mammalian working myocardium as detected with aequorin. J Mol Cell Cardiol 1985;17:1065-75.
40. Isenberg G, Klockner U, Mascher D, Ravens U. Changes in contractility and membrane currents as studied with a single patch-electrode whole-cell clamp technique. In: Noble D, Powell T, eds. Electrophysiology of single cardiac cells. London: Academic Press, 1987:25-68.
41. 2+] in mammalian ventricle: dynamic control by cellular processes. Annu Rev Physiol 1990; 52:467-85.
42. Morgan JP. Abnormal intracellular modulation of calcium as a major cause of cardiac contractile dysfunction. N Engl J Med 1991;325:625-32.
43. ++-channel blocking agents on calcium transients and tension development in isolated mammalian heart muscle. Circ Res 1983;52(suppl I):I-47-52.
44. 2+ as an inotropic mechanism. Circulation 1986;73(suppl III):III-85-98.
45. Woosley RL, Siddoway LA, Duff HJ, Roden DM. Flecainide dose-response relations in stable ventricular arrhythmias. Am J Cardiol 1984;53:59B-65B.
46. Fabiato A. Calcium-induced release of calcium from the cardiac s.r. Am J Physiol 1983;245:C1-14.
47. i transients in guinea pig ventricular myocytes. Circ Res 1987;61:148-54.
48. Beuckelmann DJ, Wier WG. Mechanism of release of calcium from sarcoplasmic reticulum of guinea-pig cardiac cells. J Physiol (Lond) 1988;405:233-55.
49. Nabauer M, Callewaert G, Cleemann L, Morad M. Regulation of calcium release is gated by calcium current, not gating charge, in cardiac myocytes. Science 1989;244:800-3.
50. 2+ transients and contraction. J Physiol (Lond) 1991;432: 283-312.
51. Kort AA, Lakatta EG. Spontaneous sarcoplasmic reticulum calcium release in rat and rabbit cardiac muscle: relation to transient and rested-state twitch tension. Circ Res 1988;63: 969-79.
52. Hille B. Ionic channels of excitable membranes. Sunderland, MA: Sinauer, 1984:272-302.
53. Martin DK, Nakaya Y, Wyse KR, Campbell TJ. Effects of disopyramide and flecainide on the kinetics of inward rectifier potassium channels in rabbit heart muscle. Br J Pharmacol 1994;111:873-9.
54. Krishnan SC, Antzelevitch CF. Flecainide-induced arrhythmia in canine ventricular epicardium. Phase 2 reentry? Circulation 1993;87:562-72.
55. Anderson JL, Platia EV, Hallstrom A, et al. Interaction of baseline characteristics with the hazard of encainide, flecainide, and moricizine therapy in patients with myocardial infarction. A possible explanation for increased mortality in the Cardiac Arrhythmia Suppression Trial (CAST). Circulation 1994;90:2843-52.
56. Sadanaga T, Ogawa S. Ischemia enhances use-dependent sodium channel blockade by pilsicainide, a class Ic antiarrhythmic agent. J Am Coll Cardiol 1994;23:1378-81.
57. Reid PR, Griffith LSC, Platia EV, Ord SE. Evaluation of flecainide acetate in the management of patients at high risk of sudden cardiac death. Am J Cardiol 1984;53:108B-11B.
58. Forbes WP, Hee TT, Mohiuddin SM, Hillman DE. Flecainide-induced cardiogenic shock. Chest 1988;94:1121.
59. Buss J, Lasserre JJ, Heene DL. Asystole and cardiogenic shock due to combined treatment with verapamil and flecainide. Lancet 1992;340:546.
60. Holtzman JL, Finley D, Mottonen L, et al. The pharmacodynamic and pharmacokinetic interaction between single doses of flecainide acetate and verapamil: effects on cardiac function and drug clearance. Clin Pharmacol Ther 1989;46: 26-32.
61. Evers J, Eichelbaum M, Kroemer HK. Unpredictability of flecainide plasma concentrations in patients with renal failure: relationship to side effects and sudden death? Ther Drug Monit 1994;16:349-51.